EPO and hepatocellular carcinoma: Our in-vivo HCC xenograft demonstrated significantly decreased HRE-luciferase intensity (p < 0.05) (Figure 6D-6E), and significantly less intratumoral EPO and VEGFA expression (p < 0.01 and p < 0.05, respectively) at the study endpoint (Figure 6E).